<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086840</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02598</org_study_id>
    <secondary_id>MDA-2003-0886</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000371619</secondary_id>
    <nct_id>NCT00086840</nct_id>
  </id_info>
  <brief_title>CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Study of CCI-779 in Patients With Relapsed, Refractory or Transformed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well CCI-779 works in treating patients with relapsed or&#xD;
      refractory chronic lymphocytic leukemia. Drugs used in chemotherapy, such as CCI-779, work in&#xD;
      different ways to stop cancer cells from dividing so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the activity of CCI-779 in patients with relapsed, refractory, or transformed&#xD;
      chronic lymphocytic leukemia.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease (relapsed or refractory chronic&#xD;
      lymphocytic leukemia [CLL] vs transformed CLL).&#xD;
&#xD;
      Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every&#xD;
      28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients achieving an objective response may receive 3 consolidation courses of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response (CR or PR)</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as the complete disappearance of all known disease, or a 50% decrease in tumor size using the sum of the product (bi-perpendicular dimensions when available).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (temsirolimus)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (temsirolimus)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
               -  Relapsed, refractory, or transformed disease&#xD;
&#xD;
                    -  Relapsed disease defined as symptomatic loss of a prior partial or complete&#xD;
                       response to a regimen containing a purine analog and/or a monoclonal&#xD;
                       antibody AND evidence of disease progression&#xD;
&#xD;
                    -  Primary resistant disease defined as failure to achieve an objective&#xD;
                       response to a regimen containing a purine analog and/or a monoclonal&#xD;
                       antibody&#xD;
&#xD;
                    -  Transformed CLL (Richters transformation), must meet both of the following&#xD;
                       criteria:&#xD;
&#xD;
                         -  Histologically confirmed lymphoma&#xD;
&#xD;
                         -  Measurable disease&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL (unless elevated due to Gilbert's disease)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL (unless due to organ leukemic involvement)&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV-positive patients allowed provide CD4 counts are normal and no AIDS-defining&#xD;
             disease is present&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to CCI-779&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic colony-stimulating factors&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior cytotoxic chemotherapy and recovered&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No other concurrent investigational or antitumor agents&#xD;
&#xD;
          -  No other concurrent cytotoxic agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Giles</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

